The North America Diabetes Care Devices Market would witness market growth of 5.1% CAGR during the forecast period (2022-2028).
Over the last few decades, the use of technology for diabetes treatment has increased, particularly among young and middle-aged individuals with type 1 diabetes. Technology's use has spread to people with type 2 diabetes as it has become more prevalent, less expensive, as well as easier to use. In addition, an increasing population of elderly have begun to use technology to manage their diabetes in recent years. Currently, significant advancements in diabetes technology include insulin delivery methods, (such as smart insulin pens and insulin pumps blood), glucose monitoring (such as CGM), and hybrid devices, which integrate glucose monitoring and insulin delivery systems. The ultimate purpose of using these technologies is to enhance glycemic management, minimize hypoglycemia risk, lessen the burden of diabetes, and enhanced the quality of life.
Blood glucose monitoring reveals how much and when a patient's body needs insulin. Blood sugar levels that fluctuate a lot can harm patients' health in a variety of ways. When blood sugar levels are too high (hyperglycemia) or too low (hypoglycemia), they can be dangerous and even fatal. Blood sugar levels can be affected by a variety of factors, including the meals a patient eats and their lifestyle. However, diabetes affects everyone differently. The impact of a food or exercise on one person's glucose levels is frequently different from that of another.
A blood sugar meter, also called a blood glucose meter or glucometer, is a portable electronic device used to measure the blood sugar in real-time to ensure it is not too high or too low. A sample of the blood is drawn on a blood lancet, an equipment that quickly pricks the skin. Place a drop on the disposable diabetic test strip's edge. Post the process, the amount of blood sugar is displayed on the monitor.
According to the National Center of Biotechnology Information, angiotensin-converting enzyme inhibitors are used to treat diabetes, and it has been shown that coronavirus binds to target cells via this enzyme, which is found in the blood vessels and lungs. As the level of the ACE2 enzyme in diabetic people rises, so do their chances of contracting COVID-19. Moreover, according to the Diabetes Research Organization, diabetes affects 34.2 million Americans or 10.5% of the population. Diabetes has been diagnosed in an estimated 26.8 million people or 10.2% of the population. In 2018, 7.3 million people in the United States had diabetes but have not been diagnosed. Diabetes affects people from all socioeconomic, economic, and ethnic groups. Type 1 diabetes affects approximately 1.6 million people and accounts for about 5.2% of all diagnosed cases of diabetes.
The US market dominated the North America Diabetes Care Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $8,197.6 Million by 2028. The Canada market is poised to grow at a CAGR of 7.5% during (2022 - 2028). Additionally, The Mexico market would display a CAGR of 6.5% during (2022 - 2028).
Based on Product, the market is segmented into Insulin Delivery Devices and Blood Glucose Monitoring Devices. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Diabetes Care Devices Market is Estimated to reach $29.3 Billion by 2028, at a CAGR of 6.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, Sanofi S.A., Zealand Pharma A/S, B. Braun Melsungen AG, Bayer AG, Abbott Laboratories, Ypsomed AG, Arkray, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Insulin Delivery Devices and
- Blood Glucose Monitoring Devices
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- F. Hoffmann-La Roche Ltd.
- DexCom, Inc.
- Novo Nordisk A/S
- Sanofi S.A.
- Zealand Pharma A/S
- B. Braun Melsungen AG
- Bayer AG
- Abbott Laboratories
- Ypsomed AG
- Arkray, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Diabetes Care Devices Market, by Product
1.4.2 North America Diabetes Care Devices Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements : 2018, Oct – 2022, May) Leading Players
Chapter 4. North America Diabetes Care Devices Market by Product
4.1 North America Insulin Delivery Devices Market by Country
4.2 North America Blood Glucose Monitoring Devices Market by Country
Chapter 5. North America Diabetes Care Devices Market by Country
5.1 US Diabetes Care Devices Market
5.1.1 US Diabetes Care Devices Market by Product
5.2 Canada Diabetes Care Devices Market
5.2.1 Canada Diabetes Care Devices Market by Product
5.3 Mexico Diabetes Care Devices Market
5.3.1 Mexico Diabetes Care Devices Market by Product
5.4 Rest of North America Diabetes Care Devices Market
5.4.1 Rest of North America Diabetes Care Devices Market by Product
Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Product Launches and Product Expansions:
6.2 DexCom, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expenses
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Product Launches and Product Expansions:
6.2.5.3 Acquisition and Mergers:
6.3 Novo Nordisk A/S
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental & Regional Analysis
6.3.4 Research & Development Expenses
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.3.5.2 Acquisition and Mergers:
6.4 Sanofi S.A.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Product Launches and Product Expansions:
6.5 Zealand Pharma A/S (Valeritas, Inc.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expenses
6.5.4 Recent strategies and developments:
6.5.4.1 Product Launches and Product Expansions:
6.5.4.2 Approvals and Trials:
6.6 B. Braun Melsungen AG
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Bayer AG
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.7.5.2 Approvals:
6.8 Abbott Laboratories
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.8.5.2 Approvals:
6.9 Ypsomed AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Recent strategies and developments:
6.9.4.1 Partnerships, Collaborations, and Agreements:
6.10. Arkray, Inc.
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Geographical Expansions:
TABLE 1 North America Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 2 North America Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Diabetes Care Devices Market
TABLE 4 Product Launches And Product Expansions– Diabetes Care Devices Market
TABLE 5 Acquisition and Mergers– Diabetes Care Devices Market
TABLE 6 Geographical expansion– Diabetes Care Devices Market
TABLE 7 Approvals and Trials– Diabetes Care Devices Market
TABLE 8 North America Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 9 North America Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 10 North America Insulin Delivery Devices Market by Country, 2018 - 2021, USD Million
TABLE 11 North America Insulin Delivery Devices Market by Country, 2022 - 2028, USD Million
TABLE 12 North America Blood Glucose Monitoring Devices Market by Country, 2018 - 2021, USD Million
TABLE 13 North America Blood Glucose Monitoring Devices Market by Country, 2022 - 2028, USD Million
TABLE 14 North America Diabetes Care Devices Market by Country, 2018 - 2021, USD Million
TABLE 15 North America Diabetes Care Devices Market by Country, 2022 - 2028, USD Million
TABLE 16 US Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 17 US Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 18 US Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 19 US Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 20 Canada Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 21 Canada Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 22 Canada Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 23 Canada Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 24 Mexico Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 25 Mexico Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 26 Mexico Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 27 Mexico Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 28 Rest of North America Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 29 Rest of North America Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 30 Rest of North America Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 31 Rest of North America Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 32 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 33 Key Information – DexCom, Inc.
TABLE 34 Key information – Novo Nordisk A/S
TABLE 35 Key Information – Sanofi S.A.
TABLE 36 Key Information – Zealand Pharma A/S
TABLE 37 key Information – B. Braun Melsungen AG
TABLE 38 Key Information – Bayer AG
TABLE 39 Key Information – Abbott Laboratories
TABLE 40 Key Information –-Ypsomed AG
TABLE 41 Key Information – Arkray, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, collaborations and agreements : 2018, oct – 2022, may) Leading Players
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 6 Recent strategies and developments: DexCom, Inc.
FIG 7 Recent strategies and developments: Novo Nordisk A/S
FIG 8 Recent strategies and developments: Sanofi S.A.
FIG 9 Recent strategies and developments: Zealand Pharma A/S
FIG 10 Recent strategies and developments: Arkray, Inc.